Depression screening predicts subsequent disability progression in people with primary progressive multiple sclerosis.

People with late-onset MS, who experience their first symptoms after age 50, tend to have faster disability progression, ...

A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability ...

Investigational vidofludimus calcium missed its primary target in an exploratory phase II study of progressive multiple sclerosis (MS) but showed promising disability-related trends, data from the ...

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of ...

PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

Fingolimod is unable to slow disability progression or brain volume loss in patients with primary progressive multiple sclerosis (MS), show the findings of the INFORMS study. The findings, which are ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUSTM ...

FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing ‌its multiple sclerosis drug candidate fenebrutinib against the relapsing form ‌of the disease achieved its ...